Lv52
1410 积分 2021-08-25 加入
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial
24天前
已完结
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)
24天前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
24天前
已完结
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
24天前
已完结
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
2个月前
已完结
KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study
2个月前
已完结
Cancer burden and control in China: landscape, trends and challenges
2个月前
已完结
Cancer burden and control in China: landscape, trends and challenges
2个月前
已完结
Genomic landscape of lung adenocarcinoma in East Asians
3个月前
已完结
Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma
3个月前
已完结
皖公网安备34019202002308
